{"id":745839,"date":"2019-12-05T06:45:00","date_gmt":"2019-12-05T06:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/"},"modified":"2025-05-12T08:57:34","modified_gmt":"2025-05-12T12:57:34","slug":"lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/","title":{"rendered":"LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer"},"content":{"rendered":"<p class=\"bwalignc\"> AstraZeneca and Merck\u2019s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Versus Placebo in BRCAm Advanced Ovarian Cancer Following Response to Platinum-Based Chemotherapy <\/p>\n<p class=\"bwalignc\"> Only PARP Inhibitor Approved in This Setting in China <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the companies have received marketing authorization from China\u2019s National Medical Products Administration (NMPA) for LYNPARZA as a first-line maintenance treatment of adult patients with newly diagnosed advanced germline or somatic <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m or s<i>BRCA<\/i>m) epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.\n<\/p>\n<p>\n<span style=\"font-weight:normal\">The approval in China is based on the results from the pivotal Phase 3 SOLO-1 trial, which were published in the <i>New England Journal of Medicine<\/i>.<i> <\/i>Results showed that LYNPARZA significantly reduced the risk of disease progression or death by 70% versus placebo in women with <i>BRCA<\/i>m advanced ovarian cancer following response to platinum-based chemotherapy (HR 0.30 [95% CI, 0.23-0.41], p&lt;0.001). At 36 months, the estimated progression-free survival (PFS) rate was 60% for women receiving LYNPARZA versus 27% for women receiving placebo. <\/span>\n<\/p>\n<p>\n<span style=\"font-weight:normal\">Of women diagnosed with ovarian cancer, 15% have a germline (inherited) mutation and 7% have a somatic (acquired) mutation in their <i>BRCA<\/i>1\/2 genes.<\/span>\n<\/p>\n<p>\nDave Fredrickson, executive vice president, oncology business unit, AstraZeneca, said, \u201cThis approval marks a new era for women with <i>BRCA<\/i>-mutated advanced ovarian cancer in China, where the prevalence of <i>BRCA<\/i> mutations in advanced disease is higher than the international average. Currently, 70% of women relapse within three years of initial treatment, representing the highest reoccurrence rate among gynecological cancers worldwide. The progression-free survival benefit of LYNPARZA observed in SOLO-1 is a significant step towards helping these women achieve long-term remission.\u201d\n<\/p>\n<p>\nDr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said, \u201cToday\u2019s approval of LYNPARZA reinforces the importance of patients knowing their <i>BRCA<\/i> mutation status at diagnosis. We are proud to provide a new option for the treatment of this devastating disease in China, and we will continue to collaborate with the Chinese government and healthcare organizations to provide LYNPARZA to patients who need it as quickly as possible.\u201d\n<\/p>\n<p>\n<span style=\"font-weight:normal\">LYNPARZA is the first PARP inhibitor approved in China for first-line maintenance in <i>BRCA<\/i>m advanced ovarian cancer. AstraZeneca and Merck are exploring additional trials in ovarian cancer and recently announced results from the Phase 3 PAOLA-1 trial, which tested LYNPARZA in combination with bevacizumab as a first-line maintenance treatment for women with advanced ovarian cancer, regardless of their biomarker status or surgical outcome.<\/span>\n<\/p>\n<p>\n<b>About SOLO-1<\/b>\n<\/p>\n<p>\nSOLO-1 was a Phase 3, randomized, double-blinded, placebo-controlled, multi-center trial to evaluate the efficacy and safety of LYNPARZA tablets (300 mg twice daily) as maintenance monotherapy compared with placebo in patients with <i>BRCA<\/i>m advanced ovarian cancer following first-line platinum-based chemotherapy. The trial randomized 391 patients with a deleterious or suspected deleterious germline or somatic <i>BRCA<\/i>1 or <i>BRCA<\/i>2 mutation who were in clinical complete or partial response following platinum-based chemotherapy. Patients were randomized (2:1) to receive LYNPARZA or placebo for up to two years or until disease progression. Patients who had a partial response at two years were permitted to stay on therapy at the investigator\u2019s discretion. The primary endpoint was progression-free survival (PFS) and key secondary endpoints included time to second disease progression or death, time to first subsequent treatment and overall survival.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwsinglebottom\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Summary of PFS<sup> i,ii<\/sup><br \/>\n<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">&nbsp;<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<i>Lynparza<\/i> (n=260)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nPlacebo (n=131)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNumber of patients with event (%)<b><br \/>\n<sup>iii<\/sup><br \/>\n<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n102 (39)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n96 (73)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nMedian PFS (in months)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNot reached\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n13.8\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nHazard ratio (95% CI)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n0.30 (0.23-0.41)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP-value\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\np&lt;0.001\n<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<sup>i Investigator-assessed<\/sup>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<sup>ii Median (interquartile range) duration of follow-up 40.7 months (34.9\u201342.9) for <i>Lynparza<\/i> and 41.2 months (32.2\u201341.6) for placebo<\/sup>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<sup>iii Analysis was done at 50.6% maturity<\/sup>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\nThe SOLO-1 safety profile was in line with that observed in prior clinical trials. The most common adverse events (AEs) \u2265 20% were nausea (77%), fatigue (63%), vomiting (40%), anemia (39%) and diarrhea (34%). The most common \u2265 Grade 3 AEs were anemia (22%) and neutropenia (9%). Seventy-one percent of patients on LYNPARZA remained on the recommended starting dose. Additionally, 88% of patients on LYNPARZA continued treatment without an AE-related discontinuation. Further, 48 percent of patients on LYNPARZA did not have a dose interruption as a result of an AE.\n<\/p>\n<p>\nThe data were presented on Oct. 21, 2018, at the Presidential Symposium of the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany and published simultaneously online in the <i>New England Journal of Medicine.<\/i>\n<\/p>\n<p>\n<b>About Ovarian Cancer<\/b>\n<\/p>\n<p>\nOvarian cancer is the eighth most-commonly diagnosed cancer and seventh most-common cause of cancer deaths in women. In 2018, there were nearly 300,000 new cases diagnosed and around 185,000 deaths. In China, there were more than 52,000 new cases diagnosed in 2018, with approximately 30,886 deaths. Most women are diagnosed with advanced (Stage 3 or 4) ovarian cancer and have a five-year relative survival rate of approximately 30%. For newly-diagnosed advanced ovarian cancer, the primary aim of treatment is to delay progression of the disease for as long as possible.\n<\/p>\n<p>\n<b>About <i>BRCA<\/i> Mutations <\/b>\n<\/p>\n<p>\n<i>BRCA<\/i>1 and <i>BRCA<\/i>2 are human genes that produce proteins responsible for repairing damaged DNA and play an important role in maintaining the genetic stability of cells. When either of these genes is mutated, or altered, such that its protein product either is not made or does not function correctly, DNA damage may not be repaired properly, and cells become unstable. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer.\n<\/p>\n<p>\n<b>About LYNPARZA<sup>\u00ae<\/sup> (olaparib)<\/b>\n<\/p>\n<p>\nLYNPARZA is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as <i>BRCA<\/i> mutations, to preferentially kill cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death. LYNPARZA is being tested in a range of tumor types with defects and dependencies in the DDR.\n<\/p>\n<p>\nLYNPARZA, which is being jointly developed and commercialized by AstraZeneca and Merck, has a broad and advanced clinical trial development program, and AstraZeneca and Merck are working together to understand how it may affect multiple PARP-dependent tumors as a monotherapy and in combination across multiple cancer types.\n<\/p>\n<p>\n<b>IMPORTANT SAFETY INFORMATION<\/b>\n<\/p>\n<p>\n<b>CONTRAINDICATIONS<\/b>\n<\/p>\n<p>\nThere are no contraindications for LYNPARZA.\n<\/p>\n<p>\n<b>WARNINGS AND PRECAUTIONS<\/b>\n<\/p>\n<p>\n<b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): <\/b>Occurred in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority of events had a fatal outcome. The duration of therapy in patients who developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of these patients had previous chemotherapy with platinum agents and\/or other DNA-damaging agents, including radiotherapy, and some also had a history of more than one primary malignancy or of bone marrow dysplasia.\n<\/p>\n<p>\nDo not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt LYNPARZA and monitor blood count weekly until recovery.\n<\/p>\n<p>\nIf the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA if MDS\/AML is confirmed.\n<\/p>\n<p>\n<b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and some cases were fatal. If patients present with new or worsening respiratory symptoms such as dyspnea, cough, and fever, or a radiological abnormality occurs, interrupt LYNPARZA treatment and initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is confirmed and treat patient appropriately.\n<\/p>\n<p>\n<b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is recommended for females of reproductive potential prior to initiating treatment.\n<\/p>\n<p>\n<i>Females<\/i>\n<\/p>\n<p>\nAdvise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 6 months following the last dose.\n<\/p>\n<p>\n<i>Males<\/i>\n<\/p>\n<p>\nAdvise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of LYNPARZA and to not donate sperm during this time.\n<\/p>\n<p>\n<b>ADVERSE REACTIONS\u2014First-Line Maintenance <i>BRCA<\/i>m Advanced Ovarian Cancer<\/b>\n<\/p>\n<p>\nMost common adverse reactions (Grades 1-4) in \u226510% of patients in clinical trials of LYNPARZA in the <b>first-line maintenance setting<\/b> for <b>SOLO-1 <\/b>were: nausea (77%), fatigue (67%), abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%), upper respiratory tract infection\/influenza\/ nasopharyngitis\/bronchitis (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%), neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI (13%), thrombocytopenia (11%), and stomatitis (11%).\n<\/p>\n<p>\nMost common laboratory abnormalities (Grades 1-4) in \u226525% of patients in clinical trials of LYNPARZA in the <b>first-line maintenance setting for SOLO-1<\/b> were: decrease in hemoglobin (87%), increase in mean corpuscular volume (87%), decrease in leukocytes (70%), decrease in lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease in platelets (35%), and increase in serum creatinine (34%).\n<\/p>\n<p>\n<b>ADVERSE REACTIONS\u2014Maintenance Recurrent Ovarian Cancer<\/b>\n<\/p>\n<p>\nMost common adverse reactions (Grades 1-4) in \u226520% of patients in clinical trials of LYNPARZA in the <b>maintenance setting <\/b>for <b>SOLO-2<\/b> were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%), nasopharyngitis\/upper respiratory tract infection (URI)\/influenza (36%), diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%), headache (26%), decreased appetite (22%), and stomatitis (20%).\n<\/p>\n<p>\n<b>Study 19: <\/b>nausea (71%), fatigue (including asthenia) (63%), vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%), constipation (22%), headache (21%), decreased appetite (21%), and dyspepsia (20%).\n<\/p>\n<p>\nMost common laboratory abnormalities (Grades 1-4) in \u226525% of patients in clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study 19<\/b>) were: increase in mean corpuscular volume (89%\/82%), decrease in hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%), increase in serum creatinine (44%\/45%), and decrease in platelets (42%\/36%).\n<\/p>\n<p>\n<b>ADVERSE REACTIONS\u2014Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n<\/p>\n<p>\nMost common adverse reactions (Grades 1-4) in \u226520% of patients in clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer after 3 or more lines of chemotherapy <\/b>(pooled from 6 studies) were: fatigue\/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%), diarrhea (31%), nasopharyngitis\/upper respiratory tract infection (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and arthralgia\/musculoskeletal pain (21%).\n<\/p>\n<p>\nMost common laboratory abnormalities (Grades 1-4) in \u226525% of patients in clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer <\/b>(pooled from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular volume elevation (57%), decrease in lymphocytes (56%), increase in serum creatinine (30%), decrease in platelets (30%), and decrease in absolute neutrophil count (25%).\n<\/p>\n<p>\n<b>ADVERSE REACTIONS\u2014g<i>BRCA<\/i>m, HER2-negative metastatic breast cancer<\/b>\n<\/p>\n<p>\nMost common adverse reactions (Grades 1-4) in \u226520% of patients in <b>OlympiAD<\/b> were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory tract infection (27%), leukopenia (25%), diarrhea (21%), and headache (20%).\n<\/p>\n<p>\nMost common laboratory abnormalities (Grades 1-4) in <span class=\"bwuline\">&gt;<\/span>25% of patients in <b>OlympiAD <\/b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%), decrease in leukocytes (71%), increase in mean corpuscular volume (71%), decrease in absolute neutrophil count (46%), and decrease in platelets (33%).\n<\/p>\n<p>\n<b>DRUG INTERACTIONS<\/b>\n<\/p>\n<p>\n<b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination with other myelosuppressive anticancer agents, including DNA-damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.\n<\/p>\n<p>\n<b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be co-administered, reduce the dose of LYNPARZA. Advise patients to avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during LYNPARZA treatment.\n<\/p>\n<p>\n<b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A inducers when using LYNPARZA. If a moderate inducer cannot be avoided, there is a potential for decreased efficacy of LYNPARZA.\n<\/p>\n<p>\n<b>USE IN SPECIFIC POPULATIONS<\/b>\n<\/p>\n<p>\n<b>Lactation: <\/b>No data are available regarding the presence of olaparib in human milk, its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infant, advise a lactating woman not to breastfeed during treatment with LYNPARZA and for 1 month after receiving the final dose.\n<\/p>\n<p>\n<b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been established in pediatric patients.\n<\/p>\n<p>\n<b>Hepatic Impairment: <\/b>No adjustment to the starting dose is required in patients with mild or moderate hepatic impairment (Child-Pugh classification A and B). There are no data in patients with severe hepatic impairment (Child-Pugh classification C).\n<\/p>\n<p>\n<b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary in patients with mild renal impairment (CLcr=51-80 mL\/min) but patients should be monitored closely for toxicity. In patients with moderate renal impairment (CLcr=31-50 mL\/min), reduce the dose to 200 mg twice daily. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr \u226430 mL\/min).\n<\/p>\n<p>\n<b>INDICATIONS<\/b>\n<\/p>\n<p>\nLYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n<\/p>\n<p>\n<b>First-Line Maintenance <i>BRCA<\/i>m Advanced Ovarian Cancer<\/b>\n<\/p>\n<p>\nFor the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m<i> <\/i>or s<i>BRCA<\/i>m) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients with g<i>BRCA<\/i>m advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n<\/p>\n<p>\n<b>Maintenance Recurrent Ovarian Cancer<\/b>\n<\/p>\n<p>\nFor the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.\n<\/p>\n<p>\n<b>Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n<\/p>\n<p>\nFor the treatment of adult patients with deleterious or suspected deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n<\/p>\n<p>\n<b>g<i>BRCA<\/i>m, HER2-negative metastatic breast cancer<\/b>\n<\/p>\n<p>\nIn patients with deleterious or suspected deleterious g<i>BRCA<\/i>m<i>, <\/i>human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n<\/p>\n<p>\n<b>Please <a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\">click here for complete Prescribing Information, including Patient Information (Medication Guide)<\/a>.<\/b>\n<\/p>\n<p>\n<b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n<\/p>\n<p>\nIn July 2017, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced a global strategic oncology collaboration to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. Working together, the companies will develop LYNPARZA and selumetinib in combination with other potential new medicines and as monotherapies. Independently, the companies will develop LYNPARZA and selumetinib in combination with their respective PD-L1 and PD-1 medicines.\n<\/p>\n<p>\n<b>Merck\u2019s Focus on Cancer <\/b>\n<\/p>\n<p>\nOur goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n<\/p>\n<p>\n<b>About Merck<\/b>\n<\/p>\n<p>\nFor more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world &#8211; including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease and infectious diseases including HIV and Ebola. For more information, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>, <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>, <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>, <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a> and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n<\/p>\n<p>\n<b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n<\/p>\n<p>\nThis news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n<p>\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s 2018 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p> Media: <br \/>Pamela Eisele <br \/>(267) 305-3558 <\/p>\n<p> Steve Wanczyk <br \/>(267) 305-5563 <\/p>\n<p> Investors: <br \/>Peter Dannenbaum <br \/>(908) 740-1037 <\/p>\n<p> Courtney Ronaldo <br \/>(908) 740-6132 <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the companies have received marketing authorization from China\u2019s National Medical Products Administration (NMPA) for LYNPARZA as a first-line maintenance treatment of adult patients with newly diagnosed advanced germline or somatic BRCA -mutated (g BRCA m or s BRCA m) epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. The approval in China is based on the results from the pivotal Phase 3 SOLO-1 trial, which were published in the New England Journal of Medicine. Results showed that LYNPARZA significantly reduced the risk of disease progression or death by 70% versus placebo in women with BRCAm advanced ovarian cancer following response to platinum-based chemotherapy (HR 0.30 [95% CI, 0.23-0.41], p&lt;0.001). At 36 months, the estimated progression-free survival (PFS) rate was 60% for<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-745839","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the companies have received marketing authorization from China\u2019s National Medical Products Administration (NMPA) for LYNPARZA as a first-line maintenance treatment of adult patients with newly diagnosed advanced germline or somatic BRCA -mutated (g BRCA m or s BRCA m) epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. The approval in China is based on the results from the pivotal Phase 3 SOLO-1 trial, which were published in the New England Journal of Medicine. Results showed that LYNPARZA significantly reduced the risk of disease progression or death by 70% versus placebo in women with BRCAm advanced ovarian cancer following response to platinum-based chemotherapy (HR 0.30 [95% CI, 0.23-0.41], p&lt;0.001). At 36 months, the estimated progression-free survival (PFS) rate was 60% for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:57:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\\\/\",\"name\":\"LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-12-05T06:45:00+00:00\",\"dateModified\":\"2025-05-12T12:57:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer - Merck.com","og_description":"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the companies have received marketing authorization from China\u2019s National Medical Products Administration (NMPA) for LYNPARZA as a first-line maintenance treatment of adult patients with newly diagnosed advanced germline or somatic BRCA -mutated (g BRCA m or s BRCA m) epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. The approval in China is based on the results from the pivotal Phase 3 SOLO-1 trial, which were published in the New England Journal of Medicine. Results showed that LYNPARZA significantly reduced the risk of disease progression or death by 70% versus placebo in women with BRCAm advanced ovarian cancer following response to platinum-based chemotherapy (HR 0.30 [95% CI, 0.23-0.41], p&lt;0.001). At 36 months, the estimated progression-free survival (PFS) rate was 60% for","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:57:34+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/","name":"LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-12-05T06:45:00+00:00","dateModified":"2025-05-12T12:57:34+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"LYNPARZA\u00ae (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b33b95a9-b4fb-464c-aa6f-6fbde676576d","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2019\/12\/1\/merck_logo.jpg","size":"21167","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/LYNPARZA-olaparib-Approved-in-China-as-a-First-Line-Maintenance-Therapy-in-BRCA-Mutated-BRCAm-Advanced-Ovarian-Cancer-2019.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745839\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745839"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}